657

Adezmapimod

657 Publications Verification

Cat. No.: HY-10256

CAS No.: 152121-47-6

Purity: 99.92%

Synonyms: SB 203580; RWJ 64809

Target:

Organoid p38 MAPK Autophagy Mitophagy HSP

Research Areas:

Inflammation/Immunology Cancer

Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC₅₀s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC₅₀s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod can inhibit p38 MAPK and lead to the inhibition of downstream HSP27 phosphorylation. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy activator .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

657

Adezmapimod hydrochloride

657 Publications Verification

Cat. No.: HY-10256A

CAS No.: 869185-85-3

Purity: 99.37%

Synonyms: SB 203580 hydrochloride; RWJ 64809 hydrochloride

Target:

Organoid p38 MAPK Autophagy Mitophagy

Research Areas:

Inflammation/Immunology Cancer

Adezmapimod (SB 203580; RWJ 64809) hydrochloride is a selective and ATP-competitive p38 MAPK inhibitor with IC₅₀s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod hydrochloride inhibits LCK, GSK3β and PKBα with IC₅₀s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod hydrochloride does not disrupt JNK activity and is an autophagy and mitophagy activator .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

500

U0126

500 Cited Publications

Cat. No.: HY-12031A

CAS No.: 109511-58-2

Purity: 98.57%

Target:

MEK Autophagy Mitophagy Influenza Virus

Research Areas:

Cancer

U0126 is a potent, non-ATP competitive and selective MEK1 and MEK2 inhibitor, with IC₅₀s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

500

U0126-EtOH

500 Cited Publications

Cat. No.: HY-12031

CAS No.: 1173097-76-1

Purity: 98.92%

Target:

MEK Autophagy Mitophagy Influenza Virus

Research Areas:

Cancer

U0126 (U0126-EtOH) is a potent, non-ATP competitive and selective MEK1 and MEK2 inhibitor, with IC₅₀s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

396

Olaparib

396 Cited Publications

Cat. No.: HY-10162

CAS No.: 763113-22-0

Purity: 99.98%

Synonyms: AZD2281; KU0059436; MK-7339

Target:

PARP Autophagy Mitophagy

Research Areas:

Neurological Disease Inflammation/Immunology Cancer

Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC₅₀s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator. Olaparib cannot cross the intact blood-brain barrier (BBB) .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

370

Mdivi-1

370 Cited Publications

Cat. No.: HY-15886

CAS No.: 338967-87-6

Purity: 99.96%

Synonyms: Mitochondrial division inhibitor 1

Target:

Dynamin Mitophagy Autophagy Apoptosis

Research Areas:

Cancer

Mdivi-1 is a selective dynamin-related protein 1 (Drp1) inhibitor. Mdivi-1 is a mitochondrial division/mitophagy inhibitor.

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

287

Ruxolitinib

287 Cited Publications

Cat. No.: HY-50856

CAS No.: 941678-49-5

Synonyms: INCB18424

Target:

JAK Autophagy Mitophagy Apoptosis

Research Areas:

Cancer

Ruxolitinib (INCB18424) is an orally active and selective JAK1/2 inhibitor with IC₅₀s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3 . Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

234

AICAR

234 Cited Publications

Cat. No.: HY-13417

CAS No.: 2627-69-2

Purity: 99.98%

Synonyms: Acadesine; AICA Riboside

Category:

Human Gut Microbiota Metabolites Natural Products Endogenous metabolite Disease Research Fields Cancer

Target:

AMPK Autophagy YAP Mitophagy Endogenous Metabolite

AICAR (Acadesine) is an adenosine analog and a AMPK activator. AICAR is also an autophagy, YAP and mitophagy inhibitor. AICAR regulates the glucose and lipid metabolism, and inhibits proinflammatory cytokines and iNOS production. AICAR inhibits autophagy through a mechanism independent of AMPK activity .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

234

AICAR phosphate

234 Cited Publications

Cat. No.: HY-13417A

CAS No.: 681006-28-0

Purity: 99.98%

Synonyms: Acadesine phosphate; AICA Riboside phosphate

Category:

Alkaloids Animals Other Alkaloids Disease Research Fields Cancer

Target:

AMPK Autophagy YAP Mitophagy Endogenous Metabolite

AICAR phosphate (Acadesine phosphate) is an adenosine analog and a AMPK activator. AICAR phosphate regulates the glucose and lipid metabolism, and inhibits proinflammatory cytokines and iNOS production. AICAR phosphate is also an autophagy, YAP and mitophagy inhibitor .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

200

Mito-TEMPO

200 Cited Publications

Cat. No.: HY-112879

CAS No.: 1334850-99-5

Purity: 99.19%

Target:

Calcium Channel PINK1/Parkin Mitochondrial Metabolism Apoptosis Autophagy NOD-like Receptor (NLR)

Research Areas:

Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology

Mito-TEMPO is a mitochondria-targeted antioxidant. Mito-TEMPO induces mitophagy by activating the PINK1/Parkin pathway, inhibits NLRP3 inflammasome activation, restores mitochondrial membrane potential, and improves renal function and podocyte injury. Mito-TEMPO regulates Ca ²⁺ homeostasis, inhibits Bnip3 overexpression, shortens action potential duration, and exerts antiarrhythmic effects. Mito-TEMPO reverses premature senescence, reduces trabecular bone loss, and decreases cell apoptosis. Mito-TEMPO can be used in studies of chronic kidney disease, age-related cardiac dysfunction, postmenopausal osteoporosis, and ischemic stroke .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

200

MitoTEMPO hydrate

200 Cited Publications

Cat. No.: HY-125944

CAS No.: 1569257-94-8

Purity: 98.03%

Target:

Mitochondrial Metabolism PINK1/Parkin NOD-like Receptor (NLR) Autophagy Calcium Channel Apoptosis

Research Areas:

Cardiovascular Disease Neurological Disease Metabolic Disease Endocrinology

MitoTEMPO hydrate is a mitochondria-targeted antioxidant . MitoTEMPO hydrate induces mitophagy by activating the PINK1/Parkin pathway, inhibits NLRP3 inflammasome activation, restores mitochondrial membrane potential, and improves renal function and podocyte injury. MitoTEMPO hydrate regulates Ca ²⁺ homeostasis, inhibits Bnip3 overexpression, shortens action potential duration, and exerts antiarrhythmic effects. MitoTEMPO hydrate reverses premature senescence, reduces trabecular bone loss, and decreases cell apoptosis. MitoTEMPO hydrate can be used in studies of chronic kidney disease, age-related cardiac dysfunction, postmenopausal osteoporosis, and ischemic stroke .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

174

Brefeldin A

174 Cited Publications

Cat. No.: HY-16592

CAS No.: 20350-15-6

Synonyms: BFA; Cyanein; Decumbin

Category:

Infection Microorganisms Macrolide Antibiotics Antibiotics Antiviral Disease Research Anticancer Disease Research Fields

Target:

Autophagy Mitophagy HSV Antibiotic Bacterial

Brefeldin A (BFA) is a lactone antibiotic and a specific inhibitor of protein trafficking. Brefeldin A blocks the transport of secreted and membrane proteins from endoplasmic reticulum to Golgi apparatus . Brefeldin A is also an autophagy and mitophagy inhibitor . Brefeldin A inhibits HSV-1 and has anti-cancer activity .

Compare

loading...